23 Jul Injectable myocardial tissue engineering product applying OPF-based hydrogel as liquid scaffold
Abstract
The invention discloses an injectable myocardial tissue engineering product applying OPF hydrogel as a liquid scaffold, in particular, the product applies the OPF hydrogel as the scaffold and combines seed cells from different sources, such as embryonic stem cells, mesenchymal stem cells, myocardial cells and the like, and the repair effect of the product on myocardial infarction regions is observed after the product is injected and transplanted into the certain regions of an animal myocardial infarction model. The product built by the scaffold can improve the retention rates and the survival rates of the seed cells, promote regeneration of the myocardial tissues, increase the ventricular wall thickness of the infarction regions, reshape the original ventricle and improve the cardiac function. The product has the characteristic of injectability and is convenient for treatment and operation, thus avoiding the risks brought by the operations such as cardiac arrest and extracorporeal circulation, etc. The invention is simple in operating process and mild in implementation conditions, provides a new product for the myocardial tissue engineering and is of great significance in the development of clinically treating heart diseases by tissue-engineered myocardium.
Year: 2010
Country: CN
Doc No: 101618235